MedTrace Logo

Mechanism Based Resistance to Aspirin

NCT00948987 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2009-10-15

No results posted yet for this study

Summary

The purpose of this research is to study why some people do not respond to the benefits of aspirin therapy. The benefit of aspirin is cardioprotection, or decreasing the risk of heart attack and/or stroke. Aspirin works by disabling the platelets, part of the blood cells used in clotting, from sticking together and forming blood clots, thus protecting the heart. It has been observed that failure to respond to aspirin therapy occurs in about 10% of the general population and that despite taking aspirin everyday, this group of non- responders is not getting protection for their heart. The investigators would like to determine why and how this happens.

Conditions

  • Aspirin Resistance
  • Pharmacological Aspirin Non-responsiveness

Interventions

DRUG

Aspirin

325 mg enteric coated single dose p.o.

Sponsors & Collaborators

Principal Investigators

  • Garret A FitzGerald, MD · University of Pennsylvania, Institute for Translationals Medicine and Therapeutics

  • Susanne Fries, MD · University of Pennsylvania, Institute for Translationals Medicine and Therapeutics

  • Tilo Grosser, MD · University of Pennsylvania, Institute for Translationals Medicine and Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2009-10-31
Completion
2009-10-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00948987 on ClinicalTrials.gov